TORL BioTherapeutics Welcomes Howard A. Burris III, MD to Its Board of Directors
TORL BioTherapeutics is thrilled to announce the appointment of Howard A. Burris III, MD, FACP, FASCO as a new board member.
This appointment marks a transformational period for TORL, an organization that is driving advancements in Antibody-Drug Conjugates (ADCs) aimed at treating cancer worldwide. Dr. Burris brings a wealth of experience in oncology and drug development, having previously held leadership roles in various significant organizations.
His strategic insights will be crucial as TORL continues its mission to enhance oncology treatments. With his involvement, TORL is poised to make substantial impacts in the biotech landscape.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.